RARA and acute promyelocytic leukemia: As expected, treatment with ATRA alone significantly increased PML-NBs in NB4 cells, a human APL cell line (M3 in the FAB classification), but not in the PML-RARA-negative HL60 cell line, which shares similar differentiation characteristics (M2) [18].